Please wait a minute...
Journal of Neurorestoratology  2018, Vol. 6 Issue (1): 67-73    doi: 10.26599/JNR.2018.9040001
Review Article     
2017 Yearbook of Neurorestoratology
Hongyun Huang1,2,(✉), Stephen Skaper3, Gengsheng Mao1, Hooshang Saberi4, Shiqing Feng5, Sang Ryong Jeon6, Lin Chen2,7, Milan Dimitrijevic8
1 Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing 100039, China
2 Cell Therapy Center, Beijing Hongtianji Neuroscience Academy, Beijing 100043, China
3 Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy
4 Department of Neurosurgery, Brain and Spinal Injury Research center, Tehran University of Medical Sciences, Tehran, Iran
5 Department of Orthopaedics, Tianjin Medical University General Hospital, Tianjin, China
6 Department of Neurosurgery, Department of Neurological Surgery, ASAN Medical Center University of Ulsan College of Medicine, Seoul, Republic of Korea
7 Department of Neurosurgery, Tsinghua University Yuquan Hospital, Beijing, China
8 Baylor College of Medicine, Houston, TX, USA
Download: PDF (245 KB)      HTML
Export: BibTeX | EndNote (RIS)      


In 2016 we published the first Yearbook of Neurorestoratology, which summarized pathogenesis in nervous system disease and damage, as well as neurorestorative mechanisms and neurorestorative therapeutic results. Given the progress and achievements occurring in 2017, we have put together those major progresses as the “2017 Yearbook of Neurorestoratology”, which can help readers to easily follow the latest developments in Neurorestoratology.

Key wordsYearbook      neurorestoratology      pathogenesis      diseases and damage to the nervous system      neurorestorative mechanisms      neurorestorative therapies     
Received: 25 March 2018      Published: 29 June 2018
Corresponding Authors: Hongyun Huang   
Cite this article:

Hongyun Huang, Stephen Skaper, Gengsheng Mao, Hooshang Saberi, Shiqing Feng, Sang Ryong Jeon, Lin Chen, Milan Dimitrijevic. 2017 Yearbook of Neurorestoratology. Journal of Neurorestoratology, 2018, 6: 67-73.

URL:     OR

[1] Huang H, Mao G, Feng S, et al. 2016 yearbook of neurorestoratology. J. Neurorestoratology 2017, 5: 111-115.
[2] Huang KL, Marcora E, Pimenova AA, et al. A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer’s disease. Nat Neurosci. 2017, 20(8): 1052-1061.
[3] Gosselin D, Skola D, Coufal NG, et al. An environment- dependent transcriptional network specifies human microglia identity. Science 2017, 356(6344): eaal3222.
[4] Kaluski S, Portillo M, Besnard A, et al. Neuroprotective functions for the histone deacetylase SIRT6. Cell Rep. 2017, 18(13): 3052-3062.
[5] Lodato MA, Rodin RE, Bohrson CL, et al. Aging and neurodegeneration are associated with increased mutations in single human neurons. Science 2017, doi: 10.1126/ science.aao4426.
[6] Shi Q, Chowdhury S, Ma R, et al. Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice. Sci Transl Med. 2017, 9(392): eaaf6295.
[7] Sprecher KE, Koscik RL, Carlsson CM, et al. Poor sleep is associated with CSF biomarkers of amyloid pathology in cognitively normal adults. Neurology 2017, 89(5): 445-453.
[8] Essuman K, Summers DW, Sasaki Y, et al. The SARM1 toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron 2017, 93(6): 1334-1343.
[9] Galindo R, Banks Greenberg M, Araki T, et al. NMNAT3 is protective against the effects of neonatal cerebral hypoxia- ischemia. Ann Clin Transl Neurol. 2017, 4(10): 722-738.
[10] Xu H, Cao Y, Yang X, et al. ADAMTS13 controls vascular remodeling by modifying VWF reactivity during stroke recovery. Blood 2017, 130(1): 11-22.
[11] Milosevic L, Kalia SK, Hodaie M, et al. Neuronal inhibition and synaptic plasticity of basal ganglia neurons in Parkinson’s disease. Brain 2017, doi: 10.1093/brain/awx296.
[12] Harting MT, Srivastava AK, Zhaorigetu S, et al. Inflammation- stimulated mesenchymal stromal cell-derived extracellular vesicles attenuate inflammation. Stem Cells 2017, doi: 10.1002/ stem.2730.
[13] Horwitz EM, Le Blanc K, Dominici M, et al. International society for cellular therapy. clarification of the nomenclature for MSC: The international society for cellular therapy position statement. Cytotherapy 2005, 7(5): 393-395
[14] Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8(4): 315-317.
[15] Galipeau J, Krampera M, Barrett J, et al. International society for cellular therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy 2016, 18(2): 151-159.
[16] Arjmand B, Safavi M, Heidari R, et al. Concomitant transurethral and transvaginal-periurethral injection of autologous adipose derived stem cells for treatment of female stress urinary incontinence: A phase one clinical trial. Acta Med Iran 2017, 55(6): 368-374.
[17] Numan MT, Kamdar A, Young J, et al.. Autologous adipose stem cell therapy for autonomic nervous system dysfunction in two young patients. Stem Cells 2017, 26(6): 391-393.
[18] Vaquero J, Hassan R, Fernández C, et al. Cell therapy as a new approach to the treatment of posttraumatic syringomyelia. World Neurosurg. 2017, 107: 1047
[19] Vaquero J, Zurita M, Rico MA, et al. Repeated subarachnoid administrations of autologous mesenchymal stromal cells supported in autologous plasma improve quality of life in patients suffering incomplete spinal cord injury. Cytotherapy 2017, 19(3): 349-359.
[20] Nguyen LT, Nguyen AT, Vu CD, et al. Outcomes of autologous bone marrow mononuclear cells for cerebral palsy: an open label uncontrolled clinical trial. BMC Pediatr 2017, 17(1): 104.
[21] Hess DC, Wechsler LR, Clark WM, et al. Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): A randomised, double-blind, placebo- controlled, phase 2 trial. Lancet Neurol. 2017, 16(5): 360-368.
[22] Osanai T, Houkin K, Uchiyama S, et al. Treatment evaluation of acute stroke for using in regenerative cell elements (TREASURE) trial: Rationale and design. Int J Stroke. 2017, 1747493017743057.
[23] Liu Y, Chen SJ, Li SY, et al. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Stem Cell Res Ther. 2017, 8(1): 209.
[24] Mandai M, Watanabe A, Kurimoto Y, et al. Autologous induced stem-cell–derived retinal cells for macular degeneration. N Engl J Med 2017, 376: 1038-1046.
[25] Huang H, Raisman G, Sanberg PR, et al. Neurorestoratology. New York, Nova Biomedical. 2015.
[26] Meng J, Zhang S, Bekyo A, et al. Noninvasive Electroencephalogram based control of a robotic arm for reach and grasp tasks. Sci Rep. 2016, 6: 38565.
[27] Gao Q, Dou L, Belkacem AN, et al. Noninvasive electroencephalogram based control of a robotic arm for writing task using hybrid BCI system. Biomed Res Int. 2017, 8316485.
[28] Nilakantan AS, Bridge DJ, Gagnon EP, et al. Stimulation of the posterior cortical-hippocampal network enhances precision of memory recollection. Curr Biol. 2017, 27(3): 465-470.
[29] Mignardot JB, Le Goff CG, van den Brand R, et al. A multidirectional gravity-assist algorithm that enhances locomotor control in patients with stroke or spinal cord injury. Sci Transl Med. 2017, 9(399): eaah3621.
[30] Thibaut A, Wannez S, Donneau AF, et al. Controlled clinical trial of repeated prefrontal tDCS in patients with chronic minimally conscious state. Brain Inj. 2017, 31(4): 466-474.
[31] Xia X, Bai Y, Zhou Y, et al. Effects of 10 Hz repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex in disorders of consciousness. Front Neurol. 2017, 8: 182.
[32] Estraneo A, Pascarella A, Moretta P, et al. Repeated transcranial direct current stimulation in prolonged disorders of consciousness: A double-blind cross-over study. J Neurol Sci. 2017, 375: 464-470.
[33] Yamamoto T, Watanabe M, Obuchi T, et al. Spinal cord stimulation for vegetative state and minimally conscious state: Changes in consciousness level and motor function. Acta Neurochir Suppl. 2017, 124: 37-42.
[34] Chudy D, Deletis V, Almahariq F, et al. Deep brain stimulation for the early treatment of the minimally conscious state and vegetative state: Experience in 14 patients. J. Neurosurg. 2017, 16: 1-10.
[35] Carlsson CA, Sundin T. In a paraplegic child. Rev Surg. 1967, 24(1): 73-76.
[36] Mohamed A, Omi E, Honda K, et al. Outcome of different facial nerve reconstruction techniques. Braz J Otorhinolaryngol. 2016, 82(6): 702-709.
[37] Zhong W, Zhang W, Yang M, et al. Impact of diabetes mellitus duration on effect of lower extremity nerve decompression in 1,526 diabetic peripheral neuropathy patients. Acta Neurochir (Wien) 2014, 156(7): 1329-1333.
[38] Yang W, Porras JL, Xu R, et al. Effectiveness of surgical revascularization for stroke prevention in pediatric patients with sickle cell disease and moyamoya syndrome. Neurosurgery 2016, 63(): 178.
[39] Egashira Y, Yamauchi K, Enomoto Y, et al. Disruption of cortical arterial network is associated with the severity of transient neurologic events after direct bypass surgery in adult moyamoya disease. World Neurosurg. 2017, 100: 311-315.
[40] Williamson RW, Abla AA, Zabramski JM, et al. Revascularization of moyamoya angiopathy in older adults. World Neurosurg. 2017, 99: 37-40.
[41] Nandra KS, Harari M, Price TP, et al. Successful reinnervation of the diaphragm after intercostal to phrenic nerve neurotization in patients with high spinal cord injury. Ann Plast Surg. 2017, 79(2): 180-182.
[42] Bertelli JA, Ghizoni MF. Nerve transfers for restoration of finger flexion in patients with tetraplegia. J Neurosurg Spine 2017, 26(1): 55-61.
[43] Medina J, Marcos-García A, Jiménez I, et al. Biceps to triceps transfer in tetraplegic patients: Our experience and review of the literature. Hand (N Y) 2017, 12(1): 85-90.
[44] Li F, Wang SF, Li PC, et al. Restoration of active pick-up function in patients with total brachial plexus avulsion injuries. J Hand Surg Eur, doi: 10.1177/1753193417728405.
[45] Zheng MX, Hua XY, Feng JT. Trial of contralateral seventh cervical nerve transfer for spastic arm paralysis. N Engl J Med. 2017, doi: 10.1056/NEJMoa1615208.
[46] Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017, 376(3): 209-220.
[47] Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017, 376(3): 221-234.
[48] Liu Y, Vollmer T, Havrdova E, et al. Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis. Mult Scler Relat Disord 2017, 11: 18-24.
[49] Cohan S, Kappos L, Giovannoni G, et al. Efficacy of daclizumab beta versus intramuscular interferon beta-1a on disability progression across patient demographic and disease activity subgroups in DECIDE. Mult Scler. 2017, 1352458517735190.
[50] Rose JW, Giovannoni G, Wiendl H, et al. Consistent efficacy of daclizumab beta across patient demographic and disease activity subgroups in patients with relapsing- remitting multiple sclerosis. Mult Scler Relat Disord 2017, 17: 32-40.
[51] Benedict RH, Cohan S, Lynch SG, et al. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: Results from the DECIDE study. Mult Scler. 2017, 1352458517707345.
[52] Edaravone (MCI-186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017, 16(7): 505-512.
[53] Rothstein JD. Edaravone: A new drug approved for ALS. Cell 2017, 171(4): 725.
[54] Warner FM, Cragg JJ, Jutzeler CR, et al. Early administration of gabapentinoids improves motor recovery after human spinal cord injury. Cell Rep. 2017, 18(7): 1614-1618.
[55] Elkins J, Veltkamp R2, Montaner J, et al. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): A randomised, placebo-controlled, double- blind phase 2 trial. Lancet Neurol. 2017, 16(3): 217-226.
[56] Ono H, Nishijima Y, Ohta S. Hydrogen gas inhalation treatment in acute cerebral infarction: A randomized controlled clinical study on safety and neuroprotection. J Stroke Cerebrovasc Dis. 2017, 26(11): 2587-2594.
[57] Brotini S, Schievano C, Guidi L. Ultra-micronized palmitoylethanolamide: An efficacious adjuvant therapy for Parkinson’s disease. CNS Neurol Disord Drug Targets 2017, 16(6): 705-713.
[58] Juhász A1, Aschermann Z1, ács P. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson’s disease: An open- label study. Parkinsonism Relat Disord. 2017, 37: 79-86.
[59] Tsai ST, Chu SC, Liu SH, et al. Neuroprotection of granulocyte colony-stimulating factor for early stage Parkinson’s disease. Cell Transplant. 2017, 26(3): 409-416.
[60] Mendell JR, Al-Zaidy S, Shell R, et al. Single-dose gene- replacement therapy for spinal muscular atrophy. N Engl J Med. 2017, 377(18): 1713-1722.
[61] Dias MF, Joo K, Kemp JA, et al. Molecular genetics and emerging therapies for retinitis pigmentosa: Basic research and clinical perspectives. Prog Retin Eye Res. 2017, doi: 10.1016/j.preteyeres.2017.10.004.
[62] Zhao Y, Tang F, Xiao Z, et al. Clinical study of neuroregen scaffold combined with human mesenchymal stem cells for the repair of chronic complete spinal cord injury. Cell Transplant. 2017, 26(5): 891-900.
[63] Huang H, Sun T, Chen L, et al. Consensus of clinical neurorestorative progress in patients with complete chronic spinal cord injury. Cell Transplant. 2014, 23(): S5-S17.
[64] Innes KE, Selfe TK, Khalsa DS, et al. Meditation and music improve memory and cognitive function in adults with subjective cognitive decline: A pilot randomized controlled trial. J Alzheimers Dis. 2017, 56(3): 899-916.
[65] Song H, Chen X, Yu Y, et al. Xingnao Kaiqiao acupuncture combined with Angong Niuhuang Wan for a patient under persistent vegetative state: A case report. Front Med. 2017, doi: 10.1007/s11684-017-0539-2.
[66] Aghayan HR, Arjmand B, Ahmadbeigi N, et al. Draft of Iranian national guideline for cell therapy manufacturing. Arch Iran Med. 2017, 20(8): 547-550.
[67] Huang H, Chen L, Zou Q, et al. Clinical cell therapy guidelines for neurorestoration (China version 2016). J Neurorestoratology 2017, 5: 39-46.
[68] Feng YP, Sun TS, Chen L, et al. Clinical therapeutic guideline for neurorestoration in spinal cord injury (Chinese version 2016). J Neurorestoratology 2017, 5: 73-83.
[69] Xiao J, Chen L, Mao G, et al. Neurorestorative clinical application standards for the culture and quality control of olfactory ensheathing cells. J Neurorestoratology 2017, 5: 175-179.
[1] Hongyun Huang, Lin Chen, Gengsheng Mao, John Bach, Qun Xue, Fabin Han, Xiaoling Guo, Ali Otom, Elena Chernykh, Edgardo Alvarez, Andrey Bryukhovetskiy, Anna Sarnowaska, Xijing He, Milan Dimitrijevic, Ihsan Shanti, Klaus von Wild, Almudena Ramón-Cueto, Ziad Alzoubi, Gustavo Moviglia, Hamid Mobasheri, Adeeb Alzoubi, Wenchuan Zhang. The 2019 yearbook of Neurorestoratology[J]. Journal of Neurorestoratology, 2020, 8(1): 1-11.
[2] Xiaoling Guo, Xin Wang, Yan Li, Bo Zhou, Weidong Chen, Lihua Ren. Olfactory ensheathing cell transplantation improving cerebral infarction sequela: a case report and literature review[J]. Journal of Neurorestoratology, 2019, 7(2): 82-88.
[3] Lin Chen, Wise Young, Gustavo A. Moviglia, Ziad M. Al Zoubi. Summary report of the 11th Annual Conference of International Association of Neurorestoratology (IANR)[J]. Journal of Neurorestoratology, 2019, 7(1): 1-7.
[4] Hongyun Huang, Hari Shanker Sharma, Lin Chen, Hooshang Saberi, Gengsheng Mao. 2018 Yearbook of Neurorestoratology[J]. Journal of Neurorestoratology, 2019, 7(1): 8-17.
[5] Zikuan Leng, Nikhit Kethidi, Allen J. Chang, Lijun Sun, Jingjing Zhai, Yiting Yang, Jianzhong Xu, Xijing He. Muse cells and Neurorestoratology[J]. Journal of Neurorestoratology, 2019, 7(1): 18-25.
[6] Qiang Ao, Juan Xiao, Yanqiu Yu, Gengsheng Mao, Qingyan Zou, Wenyong Gao, Hongyun Huang. Standards for the culture and quality control of umbilical cord mesenchymal stromal cells for neurorestorative clinical application (2017)[J]. Journal of Neurorestoratology, 2018, 6(1): 11-15.
[7] Gengsheng Mao, Yunliang Wang, Xiaoling Guo, Jun Liu, Zuncheng Zheng, Lin Chen. Neurorestorative effect of olfactory ensheathing cells and Schwann cells by intranasal delivery for patients with ischemic stroke: design of a multicenter randomized double-blinded placebo-controlled clinical study[J]. Journal of Neurorestoratology, 2018, 6(1): 74-80.
[8] Zhongju Shi, Zhijian Wei, Shiqing Feng, Gustavo Moviglia, Lin Chen, Ping Wu. Highlights for the 10th Annual Conference of the International Association of Neurorestoratology[J]. Journal of Neurorestoratology, 2018, 6(1): 84-87.
[9] Shiqing Feng, Juan Xiao, Fabin Han, Lin Chen, Wenyong Gao, Gengsheng Mao, Hongyun Huang. Neurorestorative clinical application standards for the culture and quality control of neural progenitor/precursor cells (version 2017)[J]. Journal of Neurorestoratology, 2018, 6(1): 115-119.
[10] Juan Xiao, Lin Chen, Gengsheng Mao, Wenyong Gao, Ming Lu, Xijing He, Hongyun Huang. Neurorestorative clinical application standards for the culture and quality control of olfactory ensheathing cells[J]. Journal of Neurorestoratology, 2017, 5(1): 175-179.
[11] Xiang Li, Guangsheng Li, Keith Dip-Kei Luk, Yong Hu. Neurorestoratology evidence in an animal model with cervical spondylotic myelopathy[J]. Journal of Neurorestoratology, 2017, 5(1): 21-29.
[12] Hongyun Huang, Gengsheng Mao, Shiqing Feng, Lin Chen. 2016 yearbook of neurorestoratology[J]. Journal of Neurorestoratology, 2017, 5(1): 111-115.
[13] Hongyun Huang, Lin Chen. Neurorestorative process, law, and mechanisms[J]. Journal of Neurorestoratology, 2015, 3(1): 23-30.
[14] Hongyun Huang, Gengsheng Mao, Lin Chen, Aibing Liu. Progress and challenges with clinical cell therapy in neurorestoratology[J]. Journal of Neurorestoratology, 2015, 3(1): 91-96.